Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial completed per user info (est. prim comp 2026-02-11), enrollment completed per sponsor FY2025 Q3 report. No public topline results, readout, or endpoint data found in searches across web, sponsor sites, or ClinicalTrials.gov as of Apr 2026. No clear positive/negative framing specific to this trial.
Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed85% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT06812754 (China P2, n=150, 45mg vs placebo, primary completion ~Feb 2026) is listed as completed/enrollment completed in Astellas Q3 FY2025 slides (Dec 2025) with no efficacy results, primary endpoint met statement, or interpretation provided. Unlike Japan P3 STARLIGHT 2 (explicitly 'Primary endpoint met'), no positive/negative framing or data released for this exact trial. Other fezolinetant studies (pooled/meta, different populations) are positive but not trial-specific here.
Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:19 PM
NO_DECISIONDismissed80% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov lists this study as completed but without posted results, so there is no clear public trial-specific basis yet to call the readout positive or negative.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed90% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific public efficacy readout was found. ClinicalTrials.gov showed NCT06812754 as "No Results Posted," and Astellas’ Feb. 4, 2026 pipeline update listed the China Phase 2 study only as "Enrollment completed," with no positive or negative interpretation. That is insufficient to call the readout positive or negative.
Found Apr 3, 2026, 4:07 PMReviewed Apr 3, 2026, 4:47 PM
ClinicalTrialsclinicaltrials.govDec 12, 2025, 12:00 AM
Study Details | NCT06812754 | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause
ClinicalTrials.gov lists NCT06812754 with "No Results Posted." Last update posted Dec. 12, 2025; status shown as active, not recruiting, with primary completion estimated for Feb. 28, 2026.
Sponsorirwebcasting.comFeb 4, 2026, 12:00 AM
Q3 YTD/FY2025 Financial Results Presentation | Astellas Pharma Inc.
Astellas’ Feb. 4, 2026 presentation lists China P2 NCT06812754 for moderate to severe VMS, 12 weeks, n=150, and labels it only "Enrollment completed"; no efficacy outcome is stated.
NO_DECISIONDismissed92% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No clear public efficacy readout was found for this exact trial. One trial-tracking source shows NCT06812754 with "No Results Posted," and Astellas’ Feb 2026 pipeline still lists NCT06812754 in development without any trial-specific positive or negative topline statement. That is insufficient to classify the readout as positive or negative.
Found Apr 1, 2026, 7:08 PMReviewed Apr 1, 2026, 7:16 PM